Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023820 | 0.79 | EPHX2 (0.38) | GPR3PDE2AEPHX2 | |
| SCHEMBL3184776 | 0.79 | GPR3 (0.36) | GPR3SCN9AEPHX2 | |
| SCHEMBL20930789 | 0.79 | ACHE (0.41) | ACHEGPR3PGK1FFAR4HSD11B1 | |
| SCHEMBL6024048 | 0.78 | ALDH1A1 (0.40) | — | |
| SCHEMBL6023500 | 0.77 | KDM4E (0.36) | EPHX2 | |
| SCHEMBL6023114 | 0.77 | PGK1 (0.33) | PGK1GRIN2BEPHX2 | |
| SCHEMBL10895713 | 0.76 | FFAR4 (0.39) | ACHEGPR3PGK1FFAR4GRIN2B | |
| SCHEMBL27045848 | 0.74 | FFAR4 (0.38) | ACHEGPR3PGK1FFAR4HSD11B1 | |
| SCHEMBL14032971 | 0.74 | PDE2A (0.36) | ACHEGPR3PGK1FFAR4HSD11B1 | |
| SCHEMBL13523564 | 0.73 | ACHE (0.48) | ACHEGPR3HSD11B1SCN9APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101900-B2 | Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20050187265-A1 | Novel benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | RHEINHEIMER JOACHIM (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6881742-B1 | Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187265-A1 | Novel benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides | CBR3, CBR1, CYP1B1 | ACHE 2564/4885GPR3 1061/4885PGK1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.